Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Data from new investigational studies with Novartis' Zelnorm (tegaserod maleate) show that the drug may offer a novel approach to treating upper gastrointestinal disorders.
Subscribe to our email newsletter
Zelnorm, also known in some countries as Zelmac, is currently approved for the treatment of women with irritable bowel syndrome with constipation (IBS-C) and for patients less than 65 years of age with chronic idiopathic constipation.
The findings were compiled from four Zelnorm studies presented at Digestive Disease Week 2005 and suggest the potential use of Zelnorm in upper gastrointestinal (GI) disorders, such as dyspepsia, gastroesophageal reflux disease (GERD) and functional heartburn.
“Upper GI disorders affect millions of Americans and we are encouraged to see that in addition to providing relief to millions of IBS-C and chronic constipation sufferers, Zelnorm may now offer hope to this population as well,” said Alex Gorsky, COO of Novartis. “Ongoing studies will further investigate Zelnorm’s ability to safely and effectively treat the symptoms of dyspepsia and GERD.”